StockNews.com Initiates Coverage on Sorrento Therapeutics (NASDAQ:SRNE)

StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research note issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

Sorrento Therapeutics stock opened at $0.01 on Tuesday. Sorrento Therapeutics has a 1-year low of $0.00 and a 1-year high of $0.42. The company’s 50-day moving average is $0.02 and its 200 day moving average is $0.05.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.